The State of Mushroom & Psychedelic Research: July 2026

The big picture. ShroomWire is tracking 2234 mushroom & psychedelic studies, each graded A–F for evidence strength. Here’s where the evidence actually stands right now — including how much is still early-stage, what’s preprint, and what’s been retracted.

Evidence strength across what we track

Most of the field is still early — and we think saying so plainly is the point.

What’s being researched

Early-signal & integrity watch

• 251 tracked items are preprints (not yet peer-reviewed) — promising but provisional.
• 0 are flagged retracted and are never presented as standing evidence.

Most notable studies right now

• Psilocybin-assisted therapy for major depressive disorder: Perspective from meta-analysis. — Grade A · Europe PMC
• Combined DMT–harmine formulation reduces negative self-referential emotions during social self-evaluation: a randomized — Grade B · Psychopharmacology
• Sex Differences in Acute Responses to Psychedelics: Evidence for Greater Subjective Intensity and Impairment in Female P — Grade B · bioRxiv (Cold Spring Harbor Laboratory)
• Distinct brain responses to psilocybin and escitalopram in depression captured by the Fluctuation-Dissipation Theorem — Grade B · Preprint (bioRxiv)
• Aquahenosis: A non-pharmacological altered state of consciousness induced by Floatation-REST in individuals with anxiety — Grade B · Preprint (PsyArXiv)
• Prolonged Grief Symptom Outcomes During At-Home Ketamine-Assisted Therapy: A Real-World Retrospective Analysis of 503 Ad — Grade B · Preprint (Research Square)
• Safety and Efficacy of Psilocybin in the Management of Treatment-Resistant Depression: A Systematic Review — Grade A · Preprint (Research Square)
• Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major De — Grade B · ClinicalTrials.gov
• Psilocybin Microdose for Psychological and Existential Distress in Palliative Care (PSYCHED-PAL-RCT) — Grade B · ClinicalTrials.gov
• Low doses of psilocybin as adjunct pharmacological treatment to virtual reality exposure therapy for social anxiety diso — Grade B · Preprint (PsyArXiv)

Methodology: see how we grade the evidence. This is a living snapshot, regenerated regularly from our research database. Explore every study in the Evidence Explorer.

## Educational Disclaimer

This article is for informational and educational purposes only. It is not
medical advice, mental health advice, diagnosis, treatment guidance, or a
recommendation to use any substance, supplement, therapy, or protocol.

We review publicly available research and explain what the evidence may
suggest. Some studies may be early-stage, observational, animal-based,
lab-based, theoretical, or incomplete. Always consult a qualified
professional before making health-related decisions.